SAN DIEGO, CA--(Marketwire - September 08, 2011) - SpectraScience, Inc. (OTCQB: SCIE), a San Diego-based medical device company, today announced it was recently granted a new tissue-analysis patent, further strengthening its optical biopsy patent portfolio. The patent granted is U.S. PATENT No. 8005527, "Method for Determining a Condition of a Tissue." The patent can provide the company expanded capabilities relating to its WavSTAT™ Optical Biopsy System using light-based techniques to differentiate pre-malignant from normal tissue.
"The granting of this new patent is indicative of our commitment to improving and expanding our already large intellectual property portfolio in this space. The diagnosis and detection of cancer, non-invasively using light, is becoming an increasingly more important tool for oncologists," says Michael Oliver, President & CEO of SpectraScience. Mr. Oliver continued, "We will continue to emphasize developing new intellectual property to support our current and future non-invasive, real-time cancer diagnostic systems."
SpectraScience currently holds thirty-three U.S. Patents relating to optical diagnostic systems and forceps, spectral analysis and imaging techniques. In addition, the company holds approximately twenty-five active foreign counterpart patents, primarily in the European Union and Japan.
About SpectraScience, Inc.
SpectraScience is a San Diego-based medical device company that designs, develops, manufactures and markets light-based analysis systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically diagnose tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use.